Huawei Plans to Expand AI Pharma Development With Domestic Firms as Analysts Warn of Risks
The Chinese state-linked tech giant is transforming from an ‘equipment supplier’ into an ‘industry operating system,’ one analyst said.
TL;DR
- Huawei is expanding its AI collaboration with Chinese pharmaceutical companies.
- The expansion includes the drug discovery market.
- Analysts have warned of potential risks to the Chinese public and other nations.
- Huawei's collaborations aim to deepen research in AI for the medical field.
- The company's projects are mainly with domestic drugmakers, with existing collaborations in hospitals.
- Huawei is exploring more opportunities in the healthcare sector.